Compounds > 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
Page last updated: 2024-11-03

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Psoriasis

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone has been researched along with Psoriasis in 2 studies

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.

Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rusin, LJ2
Duell, EA1
Voorhees, JJ2
Stawiski, MA1
Burns, TL1
Weinstein, GD1

Trials

1 trial available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Psoriasis

ArticleYear
Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials.
    The Journal of investigative dermatology, 1979, Volume: 73, Issue:4

    Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adolescent; Adult; Clinical Trials as Topic; Double-

1979

Other Studies

1 other study available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Psoriasis

ArticleYear
Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
    The Journal of investigative dermatology, 1978, Volume: 71, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzy

1978